This page is updated frequently with new Cytokine-related patent applications.
|Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy|
The present invention relates to a composition for expanding lymphocytes comprising at least two types of cytokines selected from interleukin 2 (il-2), interleukin 15 (il-15) and interleukin 21 (il-21). It further relates to a method of preparing a population of clinically relevant lymphocytes, comprising the steps of: obtaining a body sample from a mammal in particular a tissue sample or body liquid sample, comprising at least one lymphocyte and optionally separating the cells in the body sample, culturing the body sample in-vitro to expand and/or stimulate lymphocytes in the sample wherein the culturing comprises using il-2, il-15 and/or il-21, and optionally determining the presence of clinically relevant lymphocyte in the cultured sample.
|Medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity|
The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (has) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of has for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The applicant has in fact discovered the exclusive capacity of has in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of has vs different types and strains of herpes virus, cytomegalovirus and the virus of vesicular stomatitis.
Fidia Farmaceutici S.p.a.
|Methods of modulating inflammasome activity to treat inflammatory conditions|
Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
University Of Miami
|Pharmacophore for trail induction|
There are disclosed imidazolinopyrimidinone compounds that have activity to induce trail gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of formula i herein.
The Scripps Research Institute
|Cytokine-chitosan bioconjugates and methods of using the same|
Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders.
The Board Of Trustees Of The University Of Arkansas
|Compositions and methods for treatment of lung dysfunction|
Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines.
Children's Hospital Medical Center
|Modulating gamma-c-cytokine activity|
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
|Novel fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof|
The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor nf-κb subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of nf-κb and il-2 by competitive inhibition and inhibiting the lps-induced secretion of inflammatory cytokines and also inhibiting the production of il-2, ifn-γ, il-4, il-17a and il-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to nf-κb overactivity..
|Induction of mucosal tolerance to antigens|
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
Intrexon Actobiotics Nv
|Use of serelaxin to reduce gdf-15|
Growth differentiation factor 15 (gdf-15) is a stress-responsive cytokine known to be associated with adverse events in heart failure patients. The use of serelaxin has been shown to affect gdf-15 levels at baseline and decreases in gdf-15 levels over time.
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
The present invention includes a human lag3 functional assay using a jurkat t-cell lymphoma cell line engineered to overexpress lag3 at an optimal level relative to cd3. The assay is useful, for example, for determining the immunostimulatory properties of lag3 modulators (e.g., inhibitors or activators).
Merck Sharp & Dohme Corp.
Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction
Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.. .
Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders
The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have tlr4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company
Viral conjunctivitis treatment using ranpirnase and/or amphinase
The present specification discloses ranpirnase and amphinase, compositions comprising ranpirnase and/or amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a trna, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (ppar) pathway signal, promote the resolving phenotypic change of m1 to m2, modulate th1 and th2 cytokines, and/or reduce or suppress a nfκb pathway signal using ranpirnase, amphinase or compositions comprising ranpirnase and/or amphinase.. .
Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors
The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies..
Composition for treating inflammatory brain disease comprising stem cell-derived exosome as an active ingredient
The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema..
Samsung Life Public Welfare Foundation
Genetic engineering of macrophages for immunotherapy
Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (tme) and methods of modifying a tumor microenvironment (tme). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces t-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred nk or t cells and/or induces production of an interleukin, an interferon, a pd-1 checkpoint binding protein, hmgb1, myd88, a cytokine or a chemokine.
Seattle Children's Hospital (dba Seattle Children' S Research Institute)
Method of modulating fibroblast accumulation or collagen deposition
The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine..
Gitrl collectin fusion proteins
The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.
Single-chain fusion polypeptide comprising trail
The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Methods and bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
Thyroid hormone antagonists and their nanoparticle formulations (nanotetrac™ or nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines.
Method of treating fulminant hepatic failure using dll4 cytokine
A method of treating fulminant hepatic failure in a subject, includes administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a dll4 cytokine. A method of treating liver failure, sub-acute liver failure, chronic liver failure or acute-on-chronic liver failure in a subject, includes administering an therapeutically effective amount of a dll4 cytokine to the subject..
Compositions and methods for modulating the immune system
A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Il-17a/f heterologous polypeptides and therapeutic uses thereof
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Engineered antibody-interferon mutant fusion molecules
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (taa) antibody (ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell.
Method for inducing a trif-bias
Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (agp) crx-547 to induce a trif-biased response in a human system, which results in reduced levels of myd88-dependent cytokines relative to the myd88-dependent cytokines induced by its diastereomer agp crx-527.. .
Glaxosmithkline Biologicals S.a.
Targeted mutant alpha-helical bundle cytokines
This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells.
Enhancing serological assays via fusion proteins
A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc
Methods for catheter-based renal neuromodulation
Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Methods for therapeutic renal neuromodulation
Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Methods for diagnosing celiac disease using circulating cytokines/chemokines
Provided herein are compositions, kits, and methods for measuring circulating cytokines and chemokines in a subject that has or is suspected of having celiac disease.. .
Methods for diagnosis and prognosis of inflammatory bowel disease using cytokine profiles
The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease.
Oklahoma Medical Research Foundation
Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
Ibc Pharmaceuticals, Inc.
Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
Provided herein are immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same.. .
Ifm Therapeutics, Inc
Cancer therapy using beta glucan and antibodies
The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble beta (1,3; 1,6) glucan (nsg) enhances the tumoricidal activity of the innate immune system by binding to the c3 complement protein receptor cr3.
University Of Louisville Research Foundation, Inc.